Pediatric Pharmacy Clinical Sessions (Cert # L249215)
ACPE Numbers: Various – see listing below
Content Release Date: December 18, 2024
Expiration Date: December 16, 2025
Activity Type: Application-based
CE Credits: 4.0 hours contact (ACPE and BPS)
Activity Fee: $155 (ASHP member); $260 (non-member)
Activity Overview
This Clinical Sessions package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy.
The Pediatric Pharmacy Clinical Sessions Recertification Package consists of 3 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.
These activities are part of the ASHP and ACCP professional development program for BCPPS recertification approved by BPS. For pharmacists who maintain more than one certification, two of the activities are approved for multiple specialties (see table below).
These activities were presented as part of the 2024 ACCP Annual Meeting and 2024 ASHP Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:
- New antibiotics for gram-negative bacterial infections
- Use of biologic therapy in the management of childhood-onset systemic lupus erythematosus.
- Management of acetaminophen toxicity
Recertification Credit
Board-certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCPPS.
Learning Activity |
Passing Score |
Credit Information |
New and Pipeline Antibiotics for Gram-Negative Bacterial Infections |
70% |
1.5 Contact Hours BPS: BCCCP, BCPPS |
Leveraging Biologics: Treatment Advances in the Management of Systemic Lupus Erythematous |
66% |
1.0 Contact Hours BPS: BCPPS |
Nick-NAC APAP Whack |
76% |
1.5 Contact Hours BPS: BCCCP, BCPPS, BCEMP |
Learning Objectives
New and Pipeline Antibiotics for Gram-Negative Bacterial Infections
ACPE: 0204-9999-24-254-H01-P
- Compare the spectrum of activity, pharmacokinetics, and pharmacodynamic properties of newly approved antibiotics for the treatment of difficult-to-treat gram-negative bacterial infections in adult and pediatric populations.
- Interpret biomedical literature including study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to adult and pediatric patients with difficult-to-treat gram-negative bacterial infections.
- Given a description of an adult or pediatric patient with a difficult-to-treat gram-negative infection, design an antibiotic regimen that reflects the application of the best available evidence and current guidelines.
This activity is approved for Board-Certified Pediatric Pharmacy Specialist (BCPPS) and Board-Certified Critical Care Pharmacist (BCCCP) recertification credit.
Leveraging Biologics: Treatment Advances in the Management of Systemic Lupus Erythematous
ACPE: 0217-9999-24-069-H01-P
- Describe the pathophysiology of childhood-onset systemic lupus erythematosus.
- Evaluate current literature for the role and integration of biologic therapy in the management of childhood-onset systemic lupus erythematosus.
- Develop strategies to manage biologic therapy for hospital and health-system formularies.
This activity is approved for Board-Certified Pediatric Pharmacist (BCPPS) recertification credit.
Nick-NAC APAP Whack
ACPE: 0204-9999-24-278-H01-P
- Evaluate current guideline recommendations for patients presenting with acetaminophen toxicity.
- Develop an effective treatment regimen for the management of a patient presenting with acetaminophen toxicity.
- Develop monitoring strategies for the different medications utilized to treat acetaminophen toxicity.
- Design an effective treatment plan for patients requiring adjunctive treatment options for acetaminophen toxicity.
This activity is approved for Board-Certified Pediatric Pharmacy Specialist (BCPPS), Board-Certified Crtical Care Pharmacist (BCCCP), and Board-Certified Emergency Medicine Pharmacist (BCEMP) recertification credit.
Faculty
Kalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPAG
Clinical Professor
University of Florida College of Pharmacy
Megan Musselman, PharmD, MS, BCEMP, BCCCP, BCPS, DPLA, FASHP, FCCP
EM Clinical Pharmacy Specialist/Team Lead, PGY2 EM Pharmacy RPD
North Kansas City Hospital
Ingrid Pan, Pharm.D., BCPPS
Pediatric Rheumatology Pharmacist
Children’s Hospital Colorado
Trang D. Trinh, PharmD, MPH, BCPS, BCIDP
Associate Professor of Clinical Pharmacy
University of California, San Francisco School of Pharmacy
David E. Zimmerman, PharmD, BCCCP, BCEMP, FASHP
Associate Professor of Pharmacy, EM Pharmacist
Duquesne University
Reviewers
Sue Dombrowski, MS, RPh
Editors
Michelle Abalos, PharmD
Kristi Hofer, PharmD
Amy Holmes, PharmD, BCPPS
Anna Jackson, PharmD, BCPS
Content Matter Experts
Heather Draper, PharmD, BCPS, BCEMP
Peter Johnson, PharmD, BCPPS, BCPS, FCCM, FPPAG
Paul Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS
Jennifer Thackray, PharmD, BCPPS, BCPS
Heather Torbic, PharmD, BCPS, BCCCP, FCCM
Field Testers
Sam Abid, PharmD, BCPS, BCEMP
April Anderson, PharmD, BCPPS
Emily Ankney, PharmD, BCCCP, BCEMP
Renzio Apostol, BCPPS
Ashley Asbell, PharmD, BCCCP
Lauren Behl, PharmD, BCPPS
Sarah Belz, PharmD, BCPPS
Gideon Berdahl, PharmD, BCCCP
Heather Blue, PharmD, BCPS, BCEMP
Jessica Boben, PharmD, BCPS, BCEMP
Rebecca Bosworth, PharmD, BCPPS
Kara Boyko Frandson, PharmD, BCPS, BCEMP
Kymberly Buzzeo, PharmD, MBA, BCPPS
Anna Capulong, PharmD, BCPS, BCEMP
Laura Carson, PharmD BCCCP BCEMP
Allison Clarke, PharmD, BCEMP, BCPS
Enoch Claude, PharmD, BCPS, BCCCP
John Day, PharmD, BCPS, BCPPS
Emily Dyer, PharmD, BCPS, BCEMP
Kallie Erickson, PharmD, BCPPS
Leanna Garner, PharmD
Alexanna Gluck, PharmD, BCPPS
Nicole Goosby, PharmD, BCPPS
McKenzie Harris, PharmD, BCPPS
Jessica Hasty, PharmD, BCCCP, BCEMP
Pui Man Ho, PharmD, BCPPS
Jessica Hu, PharmD, BCCCP
Lindsay Jacobs, PharmD, MPH, BCCCP, BCEMP
Weina Jiang, PharmD, BCPS, BCEMP
Ksenya Kavva, PharmD, BCPPS
Jennifer Kim, PharmD, BCPPS
Lydia Kouletsis, PharmD, BCPPS
Miranda Lackie, PharmD, BCCCP
Michael Lake, PharmD, BCPS, BCEMP
John Littler, PharmD, BCPS, BCEMP
Jessica Ma, PharmD, BCPPS
Amanda Marrack, PharmD, BCPPS
Amy Meeker, PharmD, BCPPS
Zarema Muratova, BS Pharm, BCPPS
Duyen-Anh Pham, PharmD, BCPS, BCPPS
Brooke Raymond, PharmD, BCPS, BCPPS
Morgan Ridout, PharmD, MBA, BCCCP
Christina Riley, PharmD, BCEMP, BCCCP
Amy Rodriguez, PharmD, BCPS, BCCCP
Cathrine Roels, PharmD, BCCCP, BCEMP
Kyllie Ryan-Hummel, PharmD, BCCCP
Airka Sanchez, PharmD
Ravipal Singh, PharmD, BCEMP, BCCCP
Heather Smith, PharmD, BCPS, BCEMP
Katherine Stein, PharmD, BCPPS
Amanda Vanderwerf, PharmD, BCEMP
Kassandra Vettleson, PharmD, BCPS, BCPPS
Jontae Warren, PharmD, BCPPS
Nicole Wilcox, PharmD, BCPPS
Siu Yan Amy Yeung, PharmD, BCCCP
Abigail Zeiner, PharmD, BCPS, BCEMP
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Ingrid Pan: Gamifant Pharmacist Advisory Board, Sobi Pharmaceuticals; Pediatric Rheumatology Advisory Panel Wolters Kluwer Clinical Drug Information, Inc. | Lexicomp
Methods and CE Requirements
Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on pediatric pharmacy activities.